CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIN

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA. Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website : www.concorddrugs.in Date: 13.11.2024

To,

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal St, Fort, Mumbai, Maharashtra 400001

Scrip Code: 538965

Sub: Outcome of Board Meeting held on 13th November 2024 and Financial Results pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam,

Further to our intimation dated 6th November 2024, the Board of Directors, in meeting held today at the registered office of the company at 05:30 PM, has approved the Un-Audited (Standalone and Consolidated) financial results of the Company for the quarter ended 30th September 2024. As required by the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose/furnish the following particulars:

I. Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended 30th September 2024.

II. Limited Review Report (Standalone and Consolidated) for the Quarter ended 30th September 2024.

e

Board Meeting Concluded at 07.35 PM.

This is for the information and records of the Exchange, please.

Drugs

Thanking you

Yours Sincerely, For Concord Drugs Limited

Concord S. N-1 min NAGI REDDY SEELAM Chairman & Managing Director dera (DIN: 01764665)

SEELAM NAGI REDDY CORTAGE

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

Statement of assets and Liabilities un audited (standalone and Consolidated) for the Six Month

1 Planter		Stand	lalone	Conso	(Rs In lakh
Particulars	Note	As At 30th September, 2024	As At March 31, 2024	As At 30th September,	As At March 31, 202
ASSETS				2024	
Non-current assets				and the second second	
(a) Property, plant and equipment	3				1 1 1
(b) Capital Work-in Progress	3	1,035.84	1,098.64	1,040.17	1,103.0
(b) Investment property	3	178.34	163.05	178.34	163.
(e) Goodwill	4	63.95	63.95	63.95	63.
Financial assets	4		-		03.
(a) Investments		•			
(b) Loans & Advances	4	161.50	161.50	83.64	84.0
Other Non current assets	4	4.46	4.46	4.46	
Total Non - Current Assets	5	-		1.10	4.4
-		1,444.09	1,491.61	1,370.56	1 410 4
Current Assets		and the second second			1,419.1
Inventories					
Financial assets	7	1,828.13	1,849,93	2,435.77	
(a) Investments	a state	-		2,455.11	2,292.3
(b) Trade receivables		-	1	Print Party and Party	We like the set
(c) Coob and a line in the	6	3,016.21	2,106.95	2 2 2 2 2 2	S. S. Carlos
(c) Cash and cash equivalents	8	2.25	13.71	3,297.69	1,982.6
(d) Bank balances other than (c) above	8	3.10	3.10	2.25	14.5
(e) Other Current Financial Assets	9	6.15	4.69	3.10	3.10
Other current assets	10	192.55	159.84	24.44	4.69
Total Current assets		5,048.38	4,138.21	192.55	164.20
and store as a second second second	F		4,138.21	5,955.79	4,461.50
Fotal Assets		6,492.46	5,629.82	- 7.726.26	
QUITY AND LIABILITIES			0,023.02	7,326.36	5,880.6
quity					San Star
quity share capital	11	1,000.00	1,000.00		State Pro
Other equity	12	2,388.37		1,000.00	1,000.00
		2,000.07	2,381.78	2,388.44	2,381.78
otal Equity		3,388.37	3,381.78	2 222 44	
ön-current liabilities			5,501.70	3,388.44	3,381.78
nancial Liabilities					
(a) Borrowings	13	264.12	2.57	State Balling	
(b) Trade payables			2.67	313.12	64.54
eferred tax liabilities, net	14	46.28		24 8 4 2 B	
ovisions	15	252.88	48.15	45.46	47.33
overnment Grants	13	252.00	252.88	252.88	252.88
tal Non-current liabilities		563.27	-		
· 相關的語言是不是是自己的言語。 "我		303.27	303.70	611.46	364.76
rrent liabilities					A Designed Mars
ancial liabilities			The search search	A Strange	
(a) Borrowings	16	1,396.84	1 200 10		1. 1. 1. 1.
(b) Trade payables	17	1,052.01	1,398.13	1,596.25	1,594.87
(c) Other Current financial liabilities	18	1,032.01	354.67	1,634.12	343.75
rrent tax liabilities, net	15	25 52	92.46		92.46
ner current liabilities	19	25.53	20.24	27.79	22.34
al Current liabilities		66.45	78.85	68.30	80.70
		2,540.82	1,944.34	3,326.46	2,134.10
al liabilities		2404			
al Equity and liabilities		3,104.09	2,248.04	3,937.92	2,498.86
		6,492.46	5,629.82	7,326.36	and the second se
			NAMES OF TAXABLE PARTY.	1020.00	5,880.64

Place: Hyderabad Date: 13.11.2024 Managing Director onco

*

Ayderaba

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana Statement of standalone assets and Liabilities (un audited) Six Months period ended 30th September2024

		As At	(Rs in Lakhs
Particulars	Note	30th September,	As At
		2024	March 31, 2024
ASSETS	IS IN COLOR	2024	
Non-current assets			
(a) Property, plant and equipment	3	1.035.04	
(b) Capital Work-in Progress	3	1,035.84	1,098
(b) Investment property	3	178.34	163.
	3	63.95	63.
Financial assets			
(a) Investments			
(b) Loans & Advances	4	161.50	161.
Other Non current assets	4	4.46	4.
Total Non - Current Assets	5	and the second second	
Current Assets		1,444.09	1,491.0
Current Assets	San Provincial	and the second	
Inventories			
Financial assets	7	1,828.13	1,849.9
		ter of the headens' over 14	1,043.3
(a) Investments			新建筑的保护工作的
(b) Trade receivables	6	3,016.21	
(c) Cash and cash equivalents	8	2.25	2,106.9
(d) Bank balances other than (c) above	8	A REAL PROPERTY AND A REAL	13.7
(e) Other Current Financial Assets	9	3.10	3.1
Other current assets	10	6.15	4.6
Total Current assets		192.55	159.8
	-	5,048.38	4,138.2
Total Assets			
		6,492.46	5,629.8
QUITY AND LIABILITIES			20
quity		a series and a series of the	
quity share capital			
ther equity	11	1,000.00	1,000.00
iner equity	12	2,388.37	2,381.78
atal Fault Carte Contract			2,301.70
otal Equity		3,388.37	3,381.78
			3,301.78
on-current liabilities			
nancial Liabilities	H L Carles		
(a) Borrowings	13	264.12	
(b) Trade payables		204.12	2.67
eferred tax liabilities, net	14	45.20	
ovisions	15	46.28	48.15
overnment Grants	13	252.88	252.88
tal Non-current liabilities	1 13		
		563.27	303.70
rrent liabilities			
ancial liabilities			a san an ing ang ang
(a) Borrowings			
(b) Trade payables	16	1,396.84	1,398.13
(c) Other Current Control III I III	17	1,052.01	354.67
(c) Other Current financial liabilities	18		92.46
rrent tax liabilities, net	15	25.53	20.24
ner current liabilities	19	66.45	
al Current liabilities		2,540.82	78.85
		4,510.02	1,944.34
al liabilities		3 104 00	
al Equity and liabilities		3,104.09	2,248.04
Contraction of the Contraction o		6,492.46	5,629.82
	By (order of the Board	
	For	Concord Drugs Limited	Drugs
ce: Hyderabad	(5 No'an	540 61
e: 13.11.2024	Man	laging Director 7	2/

uo

Vida

DIN: 01764665

24						(Amount in Lakh
			Stand	lalone	Consol	idated
1	Particulars Revenue from Operations	Note	As At 30th September, 2024	As At March 31, 2024	As At 30th September, 2024	As at March 3: 2024
	A Net selectory O	HOLD				
	a. Net sales from Operations Other Income	20	1,819.42	4 225 07		1
	Total Revenue (I+II)	21	0.96	4,326.07	2,405.35	4,492.4
	iotal Revenue (I+II)		1,820.38	0.93	0.96	0.9
IV	Expenses	1.3.4		4,327.00	2,406.31	4,493.3
	a.Cost of Material Consumed b. Changes in Inventories of finished goods work in program	22	1,366.98	3,370.81	2,043.64	3,365.9
	and stock-in-trade	23	39.19	-40.49	-126.06	10.4
	c. Employees Benefit Expenses	24	191.31	105.01		-40.4
	d. Finance Costs	25	75.78	495.04	239.20	607.6
	e. Depreciation and Amortisation expense	3	67.63	158.98	91.87	186.76
	f. Other expenses	26	69.49	153.82	68.27	155.54
	Total Expenses	F	1,810.37	132.99	78.74	155.15
	Profit/ (Loss) before Exceptional item and tax (III-IV)	F	10.01	4,271.16	2,395.65	4,430.48
	exceptional Items		10.01	55.84	10.66	62.90
	Profit/ (Loss) before tax (V+VI)		10.01	-		
	Tax Expense:		3.42	55.84	10.66	62.90
- C	a. Current tax	Roselli	5.29	13.90	3.58	15.66
1	b. Deferred tax charge/credit			20.24	5.46	22.01
	Profit/ (Loss) for the period (VII-VIII)	H	-1.87	-6.34	-1.87	-6.36
1	Other Comprehensive Income		6.59	41.94	7.07	47.24
1	tems that will not be reclassified to profit or loss			-		Sec. Carlor
٦P	Iotal Comprehensive Income for the period (comprising	H	-			
1	IX+X)		6.59	41.94	7.07	47.24
0	Paid-up equity share capital Face value of the share- Rs. 10 each)		1,000.00	1,000.00	1,000.00	1,000.00
E	arnings per share (of Rs. 10 each)					
	Basic (in Rs)		0.07			3.4.28 1.88
D	. Diluted (in Rs)		0.07	0.42	0.07	0.47

Place: Hyderabad Date: 13.11.2024 For Concord Drugs Limited Limited

5

* Concord Drug

S. N-1 Ace Managing Director DIN: 01764665

Concord Drugs Limited

Survey No 249, Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Un Audited Statement Of Standalone Profit and Loss for the Six Months period ended 30th September 2024

1	Particulars	Note	As At 30th September, 2024	As at March 31, 2024
1	Revenue from Operations			
	a. Net sales from Operations	20	1,819.42	
	Other Income	21	0.96	4,326.0
	Total Revenue (I+II)		1,820.38	0.9 4,327.0
IV	Expenses			4,327.0
	a.Cost of Material Consumed			
	b. Changes in Inventories of finished and the	22	1,366.98	3,370.8
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	39.19	
	c. Employees Benefit Expenses		39.19	-40.49
	d. Finance Costs	24	191.31	495.04
	e. Depreciation and Amortisation expense	25	75.78	158.98
	f. Other expenses	3	67.63	153.82
	Total Expenses	26	69.49	132.99
	Profit/ (Loss) before Exceptional item and tax (III-IV)	4	1,810.37	4,271.16
V	Exceptional Items		- 10.01	55.84
VI	Profit/ (Loss) before tax (V+VI)	-	man and second second second	Same State State
VII	Tax Expense:		10.01	55.84
111	a. Current tax		3.42	13.90
	b. Deferred tax charge/credit		5.29	20.24
X	Profit/ (Loss) for the period (VII-VIII)	-	-1.87	-6.34
x	Other Comprehensive Income		6.59	41.94
•	Items that will not be reclassified to profit or loss			
	Total Comprehensive Income for the period (comprising	-	-	
	(IX+X)		6.59	41.94
(1	Paid-up equity share capital		1,000.00	
	(Face value of the share- Rs. 10 each)		1,000.00	1,000.00
11	Earnings per share (of Rs. 10 each)			All started and the
11	a. Basic (in Rs)		0.07	
1216	b. Diluted (in Rs)			0.42
	Spland particular and a second se	_	0.07	0.42

5, N-1 ray Managing Director Place: Hyderabad Date: 13.11.2024 DIN: 01764665



1	Distance of the second s		Ourselowly and ad				[Rs. in Lakhs]
	PARTICULARS	30-09-2024	30-04-2024	20.00 0000	Half Yea	Half Year ended	Series and a series of the ser
-	Revenue from Operations	(Un Audited)	(Un Audited)	SU-09-2023 [Un Audited]	30-09-2024	30-09-2023	31-03-2024
	a. Net sales from Operations		And And And		(naumer and	(on Auaited)	(Audited)
	b. Other Operating Income	1,236.07	1,169.29	751.67	2,405,35	1 640 83	
=	Other Income	0.96	00.00	0.81		1,049.00	4,492.45
	Total Revenue (I+II)	-	-			10'0	0.93
IV	Expenses	1,237.02	1,169.29	752.48	2,406.31	1.650.65	4 402 20
	a Cost of Material Consumed					CONCONT	4,493.38
	b. Changes in Inventories of finished goods work in	1,176.65	866.98	488.08	2 043 64	1 002 64	
	c. Employees Benefit Exnenses	-161.22	35.16	-78.94	20.222.2	100010	3,365.90
	d. Pinance Costs	93.39	145.81	146 33	00.027-	84.96-	-40.49
	e. Derrectation and American	46.59	45.28	CC-DLT	12.457	284.64	607.63
	f Other succession	34.41	33 07	C0.24	48.16	86.71	186.76
	Total Business	40.63	100.00	38.83	68.27	71.17	155.54
	Profit / (nee) hofens Provide State Profit / (nee) hofens Provide State Provide Stat	1,230.45	1165 20	57.05	78.74	70.78	155.15
2	Eventional terms	6.57	DT COTT	80.210	2,395.65	1,507.33	4,430.48
1	Profit / floor) hoten and the	j .	00**	08.61	10.66	143.31	62.90
IIA	Tax Expenses	6.57	4.08	70.01			
VIII	a. Current tax	2.23	1.35	73.67	00'01	143.31	62.90
0	b. Deferred tax charoe /credit	2.63	2.83	CL 76	9000	38.07	15.66
IX	Profit/(Lose) for the neriod (VII. VIII)	-0.40	-1.47	110	101	42.37	22.01
x	Other Commembersive Income	4.34	2.73	56 18	10.1-	-4.30	-6.36
	Iteme that will not be not the set				10.1	105.24	47.24
	Total Comments and will find the reclassified to profit or loss						
	commrehending income for the period (comprising profit and other				,		
IX	Paid up Capital	4.34	2.73	56.18	7.07	105.24	47.24
	(Face value of the share. Re 10 each)	1,000.00	1,000.00	93155	1 00000		
	Other Equity				nnnnnt	931.55	1,000.00
ШХ	Earnings per share (of Rs 10 each)						
IIIX	a. Basic (in Rs)	2,388.37	2,382.95	2,382.52	2 388 37	2 207 57	00 100 0
	b. Diluted (in Rs)	0.04	0.03	0.60	0.07	21.200.12	8/-196'7
		0.04	0.03	0.60	0.07	112	14.0
Notes:						0110	14.0
1	The finnacial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 read with the advisor	ng Standards (Ind AS)	prescribed under sec	ction 133 of the Co	ompanies Act 201	Tranch with the	
	The above standalone financial results as reviwed by the multi-section of the standalone financial results as reviwed by the section of the s						CICVANT
2	a service of the autit committee have been approved by Board of Directors at its meeting held on 13th November, 2024	by Board of Directors	it its meeting held o	n 13th November,2	2024		
m	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with currons particular and an event of the correspondence of	ed necessary to corre	soond with current .	and a second second			
1	the results are also available on the contraction of the			ocnod s presentativ	on.		
4	and the company www.concorddrugs.in						
					By	By Order of the Board	p
of Hu	Place: Hudonshad				Foi	For Concord Drugs Limited	Limited
e: 13.	Date: 13.11.2024				2°	えったいか	I



Image: Section of the progress and indication of the progress of the progress and indication of the progress			-					[Rs. in Lakhs]	State of the state
Interfactor Interfactor <thinterfactor< th=""> <thinterfactor< th=""></thinterfactor<></thinterfactor<>		PARTICULARS	100 00 00	Quarterly ended		half yea	ar ended		
One of the interval inter	-	Rotsento from Amoral	sub-09-2024 (un Audited)	30-06-2024 [un Audited]	30-09-2023	30-09-2024	-	31-03-2024	
Constraint Constra		a. Net sales from Operations	AND A CONTRACT		6	(nationer and	_	(Audited)	
Intermeter Interme		1	1,184.11	635.32	738.23	1,819.42	1,617.07	4.326.07	
at a control of the formation of the for			0.76	0.00	0.81	0.96	0.81	0.93	
Material Comment of Natural	2		1,185.06	635.32	739.04	1.82038	1 617 00		
and interface and stack-in-tradient and stack-in-trade and stack-in-	1.1	1				Decosole .	00'/TD'T	4,327,00	
Owner Statute Out Display Display <thdisplay< th=""> <</thdisplay<>		b. Changes in Inventorios of Anished and a feature	979.05	387.92	473.67	1 366 98	1 047 96	FO ULC C	129
or contrast Bits Total Total <thtotal< th=""> Total Total</thtotal<>		C. Fundamers Ranaft Expansion	4.03	35.16	-44.95	39.19	64 62 ·	10.0104	and the second s
State State <th< td=""><td></td><td>d. Finance Coste</td><td>86.12</td><td>105.19</td><td>127.83</td><td>191 31</td><td>61.30</td><td>401-44</td><td>State of the state</td></th<>		d. Finance Coste	86.12	105.19	127.83	191 31	61.30	401-44	State of the state
Constraint State		e. Donneristion and Amontonion	38.75	37.03	39.03	75.78	20.07	c0.04+	
Constraint Constraint <thconstraint< th=""> Constraint Constrai</thconstraint<>		f Other evenesses	34.09	33.54	38.41	67 63	10.01	86'8CT	
(1,17)(6) (0.32) (0.3		Tatal Evinement	35.65	33.83	28.81	0000	10.32	78.541	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Design in the second se	1.177.69	637.68	10 633	4 04 0 00	18'65	132.99	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	1	÷.,	7.37	2.64	10'700	1,810.57	1,478.66	4,271.16	
Table Total Total <tt< td=""><td>1</td><td>1.5</td><td></td><td></td><td>14-01</td><td>TO'NT</td><td>139.23</td><td>55.84</td><td></td></tt<>	1	1.5			14-01	TO'NT	139.23	55.84	
the direct changing fraction of the contract o		-	7.37	2.64	76.24	10.01			
at dual manufacture in the constraint of the con			1.96	1.47	73.61	TO'NY	57.6CT	55.84	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			2.90	530	CL VC	3.44	31.94	13.90	
Bit Market State St		b. Deterred tax charge/credit	-0.95	660-	21.72	67.5	42.24	20.24	
Other relation to the reduction of the relation of the relation of the relation of the period (comprising profit and other arrive house for the period (park) 1.1.1 2.2.82 5.4.2 1.1.1 1.1.2 5.1.9.4 miprofensive humane for the period (comprising profit and other the period (park) 1.000.00 931.55 1.000.00 931.55 1.000.00 topical 2.388.37 2.388.37 2.382.52 2.388.37		Fromt/ (Loss) for the period (VII-VIII)	547	1 17	11.1-	18.1-	-4.30	-6.34	
at vial income for the period (comprising profit and other period (comprising profit and other period (comprising profit and other the period (comprising profit and other capital		Other Comprehensive Income	-	111	20.26	629	101.28	41.94	
maryrefreating fracture for the period (comprising profit and other theraise income for the period (comprising profit and other theraise income for the period (comprising profit and other to of the sinue. Rs. 10 each) Copial copial to of the sinue. Rs. 10 each) copial to of the sinue Rs. 10 each) copial theraise (of Rs. 10 each) the sinue Rs. 10 each Rs. 10 each) the sinue Rs. 10 each Rs. 10 each Rs. 13 each Rs. 238.37 the sinue Rs. 13 each Rs. 13 each Rs. 13 each Rs. 2013, read with the the sinue Rs. 13 each Rs. 14 for the Rs. 12 each Rs. 2013, read with the Rs. 12 each Rs		Items that will not be reclassified to profit or loss					-	-	
Tentiative income for the periad) (TX-X) 5.42 1.11 22.62 6.59 10.128 4.194 4.1		Total Comprehensive Income for the period (comprising profit and other					•	•	
lar frautuse. Rs. 10 each) the reframe. Rs. 10 each) the Parameter (of Ks. 10 each) the Company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) preserbed under accion 133 of the Companies Act. 2013, read with the the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous period are to the Company www.concorderugs. The corresponding previous period are to the company www.concorderugs. The corresponding previous period are to the company www.concorderugs. The corresponding previous period are to the company wherever correspond w		comprehensive income for the period) (IX+X)	5.42	1.17	52.62	6.59	101.28	41.94	
up of the source stature. Is, 10 each) 2,388.37 2,382.32 2,382.32 2,382.32 2,382.32 2,381.39 s per share (of Rs, 10 each) 0.05 0.01 055 0.07 11.09 0.23 in Rs) 0.05 0.01 055 0.07 11.09 0.23 in Rs) 0.05 0.01 055 0.07 11.09 0.23 in Rs) 0.05 0.01 0.55 0.07 10.9 0.23 in Resided interviewed by the ender in Accounting standards (In ASI) prescribed under section 13.3 of the Companies Act, 2013, read with the in Accounting standards in the inderviewed by the outer section 13.3 of the Companies Act, 2013, read with the in standaling previous periods are regrouped and rectassified wherever conderever to contespond with current period's presentation. is a standards in Accounting standards the origits of the Company www.concorddrugs.in is a standard of Directors at its			1,000.00	1 000 00	021 CC	1 000 00			
Image: Single (of Rs. 10 each) 2,382.35 2,382		(Face value of the share- Rs. 10 each) Other Emilty			CCTCL	1'00000	931.55	1,000.00	
in R3 in R3 (in R4) (in R4)		Earnings ner chera (AFDs 10	2,388.37	2,382.95	2,382.52	2.388.37	2 382 53	06 106 6	
Image: contract of the company have been prepared in accordance with the indian Accounting Standards (Ind AS) 0.01 0.56 0.07 1.09 0.42 ial results of the company have been prepared in accordance with the indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the value to make the audit committee have been approved by Board of Directors at its meeting held on ±11.2024 0.07 1.09 0.42 Is studione financial results as reviveed by the audit committee have been approved by Board of Directors at its meeting held on ±11.2024 Internet period's presentation. Internet period's presentation.		a Rasir fin Re)					Terroria	0/.100'7	
Insultion 0.05 0.01 0.56 0.07 1.09 0.42 Insults of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the standalone financial results as revived by the audit committee have been approved by Board of Directors at its meeting held on £3.11.2024 0.07 1.09 0.42 Index issued there under. Istandalone financial results as revived by the audit committee have been approved by Board of Directors at its meeting held on £3.11.2024 Index is the companies Act, 2013, read with the final accounding previous period are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. By Order of the Board final Accounting Standards (Ind AS) prescribed under section 13.3 of the Companies Act, 2013, read with the text as a size also available on the webiste of the Company www.concorddrugs.In By Order of the Board final Accounting Standards (Ind AS) prescribed under section 13.1.2024		b. Diluted (in Re)	0.05	0.01	0.56	0.07	1 00	CV 0	
tial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the late is standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on £3.11.2024 If the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. If the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. If a corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. If a re also available on the webite of the Company www.concorddrugs.in a ste also available on the webite of the Company www.concorddrugs.in DIN: 01764665			0.05	0.01	0.56	0.07	1 09	24.0	
tial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the Uder section 133 of the Companies Act, 2013, read with the standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 13.11.2024 If the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. By Order of the Board For Concord Drugs Limited For Concord Drugs For Concord Dru	1 14						-	72.0	
standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on £3.11.2024 the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are also available on the webiste of the Company www.concorddrugs.Im		The finnacial results of the company hav been prepared relevant rules issued there under	ounting Standards (In	id AS) prescribed un	der section 133 of	the Companies A	of 2013 read with		
standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on £3.11.2024 the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. The corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. By Order of the Board For Concord Drugs Limited DIN: 0.1764665 DIN: 0.1764665	11						INA POST CTOT IN		
the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. a are also available on the webiste of the Company www.concorddrugs.in By Order of the Board For Concord Drugs Limited DIN: 01764665 DIN: 01764665		ine above standaione financial results as reviwed by the audit committee have been appr	oved by Board of Dire	ctors at its meeting	held on 13.11.202	4			
s are also available on the webiste of the Company www.concorddrugs.in By Order of the Board For Concord Drugs Limited Managing Director DIN: 01764665 DIN: 01764665		Figures of the corresponding previous periods are regrouped and reclassified wherever con	nsidered necessary	141 - Frankriker				1	
a are also available on the webiste of the Company www.concorddrugs.in By Order of the Board Per Concord Drugs Limited				correspond with cu	Irrent period's pres	sentation.			
By Order of the Board For Concord Drugs Limited		The results are also available on the webiste of the Company www.concorddrugs.in							
For Concord Drugs Limited						Bv	Order of the Ros		
Managing Director 1 95						Fo	ar Concord Drugs	I.	*]
Managing Director	sales 1	yderabad		1000			2 112 5	2	291
t concor	per l	3.11.2024				Ma	anaging Director		e1e
						5	C0040/Th	uar	12A
								- Call	

CASH FLOW FROM OPERATING ACTIVITIES September 30, 2024 March 31, 2026 Profit Before Tax Additionet for; Additionet for; Profit Construct of ASSess 10.66 62. Depreciation and amortisation expense Finance costs 91.87 155.54 55.64 Interest income. 91.87 158.76 -0.93 Operating profit Sefore Working capital changes 0.36 -0.93 341.1 Concest in WANNES 91.87 159.38 404.1 Adjustment for Increase / decrease in operating assets: -0.36 -0.93 341.1 Conset in WANNES -1.315.02 -00.165 -0.93 -0.165 Other Non Current assets -1.33.66 -28.58.4 -00.165 -0.03 Other Non Current assets -1.33.76 -9.35 -0.00 -0.00 -0.03 -0.00	Bush 1		-		(A	mount in Lakl
Profit Before Tax 10.66 52. Adjustments for and amortisation expense 68.27 15.5.54 Provision of Cratuity -0.96 -0.93 Operating profit before working capital changes -0.96 -0.93 Concers in working control. (Netro Note 40) -0.96 -0.93 Adjustments for increase / decrease in operating assets: -0.96 -0.93 Trade receivables -0.97 -0.06 Lonan and Advances -0.97 -0.73 Other Non Current assets -0.43.46 -0.93.5 Other Non Current assets -1.97.6 9.33.5 Other Current tassets -1.97.6 9.33.5 Other Current tassets -1.97.6 9.33.5 Other Current financial labitities -2.26.3 -70.00 Other current financial labitities -2.26.0 -0.03 Other current financial labitities -2.26.1 -0.03 Other current financial labitities -2.26.1 -2.00.9 Provisions -2.26.1 -2.20.1 -2.03 Other current financial labitities -2.20.1	Particulars				A	As at
Adjustments for: 10.66 62. Depreciation and amorisation expense 65.27 135.54 Provision for Gratuty -0.96 -0.93 Operating profile before working capital changes 10.66 40.2 Choncer in working capital changes 159.18 341.3 Choncer in working capital changes 10.66 40.2 Choncer in working capital changes 10.66 40.2 Choncer in working capital changes 1.315.02 -40.166 Choncer in working capital changes -43.346 -22.35 Other Sonk latances -0.37 -40.166 Other Sonk latances -0.37 -40.166 Other Sonk latances -1.315.02 -40.166 Other Current sasts -1.33.76 9.33 Other Current sasts -1.33.76 9.33 Other Current financial Assets -1.32.40 -1.00 Other Current financial liabilities -22.46 9.71 Other current financial liabilities -22.46 9.72 Other current financial liabilities -22.46 -9.00 Other current financial liabilities -22.46 -9.00 Other current financial liabilities -22.45 -0.00 Other current financial liabilities -20.11 -01.	A. CASH FLOW FROM OPERATING ACTIVITIES	The second	Septemi	per 30, 2024	March	31, 2024
Profit on sets of Assers 66.27 155.54 Depreciation and amonitastion expense 66.27 155.54 Provision for Gratuity -0.96 -0.93 Operating profit before working capital changes -1.915.93 -0.94 Quarteriating for increase / decrease in operating assets: -1.915.02 -401.66 Trade receivables -1.915.02 -401.66 Long and Advances -1.915.02 -401.66 Other Non Current assets -1.915.02 -401.66 Other Non Current assets -1.915.02 -401.66 Other Current inscall Assets -1.935.02 -401.66 Other Current inscall assets -1.937.6 -9.35 Adjustments for inancela Xsets -1.93.76 -9.35 Other Current inancial Inscall Xsets -1.9.76 -9.35 Current tax inabilities -2.24.6 -9.71 Trade necelables -1.00.9 -100.09 Current tax inabilities, net -2.26.6 -9.72 Trade necelables -1.23.0 -100.9 Current tax inabilities, net -2.20.11 -101.79 Current tax inabilities, net -2.20.11			1.1.1.1.1.1.1.1.1	10.0		
Depretation and amortisation expense 66.27 155.54 Prance costs 91.87 136.76 Operating profit before working capital changes 159.18 341.13 Common moving capital changes 140.46 464.17 Prancial Assets -40.73 464.17 Trade receivables -40.73 -40.1.66 Coher Non Current assets -1.315.02 -401.66 Other Current assets -1.315.02 -401.66 Other Current tassets -1.315.02 -401.66 Other Current financial labilities -28.23 -75.00 Other current financial labilities -24.64 9.71 Other current financial labilities -24.64 9.71 Other current financial labilities -24.64 9.71 Other current financial labilities -24.65 -20.01 Other current financial labilities -24.65 -20.01 </td <td></td> <td></td> <td>1.</td> <td>10.60</td> <td></td> <td>62.</td>			1.	10.60		62.
Pinance costs interest income 98.87 91.87 135.54 91.87 Provision for Gratuity 0.96 -0.93 Operating profit before working capital changes 159.18 341.1 Changes in working capital changes 169.84 406.2 Cancers in working capital changes 169.84 406.2 Changes in working capital changes 169.84 406.2 Changes in working capital changes -1.315.02 -401.66 Changes in working capital changes -0.33 -0.33 Interest income 0.073 -0.33 Interest income assets -1.431.60 -285.84 Other Current assets -1.434.66 -285.84 Other Current insancial liabilities -1.976 9.35 Adjustments for increase / ideorease in operating liabilities: -1.976 9.35 Trade payables -1.290.37 -1.383.47 Other current inancial liabilities -1.0.69 -1.0.09 Current tax liabilities, net -1.240 -1.0.29 Provisions -1.455.77 100.28 Cash flow from operating activities (a) -3.66 -3.73 Cash flow from operating activities (b) -3.66 -3.73 Deferred tax on analgamation -3.66 -3.73 Cash flow from operat	Poprovinties and a set		The second	Sector State	and a start	
Interest income 91.87 135.78 1	Einance costs		68.2	7		
Provision for Gratuity -0.96 -0.93 Operating profit before working capital changes -0.93 3413 Changes in working capital changes -0.93 3413 Changes in working capital changes -0.93 3413 Changes in working capital changes -0.93 404.4 Adjustments for (increase) / decrease in operating assets: -0.93 404.4 Trade receivables -1.33.02 -401.66 Coher Non Current assets -1.43.46 -28.58 Other Current mascial sosts -1.33.70 9.35 Adjustment for increase / (decrease) in operating liabilities: -1.29.37 -1.38.47 Other current financial liabilities -9.26 9.71 Sorrowings -1.24.6 -1.0.93 Other current financial liabilities -2.26 -2.7.9 Provisions -5.46 -1.5.79 Deferred tax on analgamation -1.45.77 101.24 Cash flow from operating activities (A) -20.11 -101.78 Addiust explicities -20.11 -101.78 Create time and advances -20.11 -101.78 Addiust explicities -20.11 -101.78 Correct time for operating activities (B) -0.95 -0.99 Addiust explicities -					and the second sec	
Operating profit before working capital changes 159.18 341. Changes in working capital changes 169.84 406.3 Adjustments for (increase) / decrease in operating assets: -1.315.02 -401.66 Trade receivables -1.315.02 -401.66 Other Non Current assets -1.335.02 -401.66 Other Vanc Manness -28.35 570.000 Other Current assets -1.335.02 -401.66 Other Current assets -1.335.02 -401.66 Other Current financial Assets -1.335.02 -401.66 Other Current financial Inbilities -1.20.3 -1.00 Trade payables -1.20.37 -383.47 Other current financial Inbilities -9.246 -9.71 Other current financial Inbilities -9.246 -9.71 Fride payables -9.246 -9.71 Other current financial Inbilities -9.246 -9.71 Current tax indimities, net -9.26 -9.72 Provisions -9.245 -9.20 Cash flow from operating activities (A) -9.25 -9.26					and the second sec	1921
Character in working coupling. (Nefer Note 40) 169.84 404.3 Adjustments for (increase) / decrease in operating assets: -1,315.02 -401.65 Financial Assets -1,315.02 -401.65 Other Non Current assets -143.46 -285.84 Other Von Current assets -143.46 -285.84 Other Von Current assets -143.46 -285.84 Other Current financial Assets -13.76 9.35 Adjustments for increase / (decrease) in operating liabilities: -1.00 9.35 Trade payables -1.200 -0.03 Other current financial Habilities -92.46 9.71 Other current financial Habilities -92.46 9.71 Other current financial Habilities -24.67 -100.09 Other current financial Habilities -24.65 -5.79 Deferred tax on amalignmation -145.77 101.24 Sch generated from operating activities (A) -20.11 -101.79 Vectored tax on amalignmation -28.54 -20.11 -101.79 Sch generated from operating activities (B) -0.96 0.93 ASH FLOW ROM INVESTING ACTIVITIES -91.87 -126.76 Others -19.15 -100.86 Tothers -13.81 -127.26 <t< td=""><td>Provision for Gratutly</td><td></td><td>-0.9</td><td>0</td><td>-0.93</td><td>1.5</td></t<>	Provision for Gratutly		-0.9	0	-0.93	1.5
Character in working coupling. (Nefer Note 40) 169.84 404.3 Adjustments for (increase) / decrease in operating assets: -1,315.02 -401.65 Financial Assets -1,315.02 -401.65 Other Non Current assets -143.46 -285.84 Other Von Current assets -143.46 -285.84 Other Von Current assets -143.46 -285.84 Other Current financial Assets -13.76 9.35 Adjustments for increase / (decrease) in operating liabilities: -1.00 9.35 Trade payables -1.200 -0.03 Other current financial Habilities -92.46 9.71 Other current financial Habilities -92.46 9.71 Other current financial Habilities -24.67 -100.09 Other current financial Habilities -24.65 -5.79 Deferred tax on amalignmation -145.77 101.24 Sch generated from operating activities (A) -20.11 -101.79 Vectored tax on amalignmation -28.54 -20.11 -101.79 Sch generated from operating activities (B) -0.96 0.93 ASH FLOW ROM INVESTING ACTIVITIES -91.87 -126.76 Others -19.15 -100.86 Tothers -13.81 -127.26 <t< td=""><td>Operating on the s</td><td></td><td>1. S. C. C. C. C. C. C.</td><td>150.00</td><td></td><td></td></t<>	Operating on the s		1. S. C. C. C. C. C. C.	150.00		
Adjustments for (increase) / decrease in operating assets: -1,315.02 -401.65 Trader receivables -1,315.02 -401.65 Cher Ron Current assets -143.46 -285.84 Other Vancent assets -123.75 -335 Inventories -28.35 570.00 Other Current assets -13.76 -335 Adjustments for increase / Idecrease) in operating liabilities: -13.76 -335 Trade apyables -2.246 -0.71 -0.09 Dother Current financial liabilities -92.46 -9.71 -0.09 Other current financial liabilities -92.46 -9.71 -0.09 Other current financial liabilities -92.46 -9.71 -0.09 Other current financial liabilities -92.46 -9.71 -0.09 Current tax inbilities, net -12.40 -10.09 -0.09 Provisions Deferred tax on amalgamation 5.46 -15.79 -0.24 Cash flow from operating activities (A) -20.11 -101.79 -01.24 Cash flow from operating activities (B) 0.96 -0.93 -0.93 Cash flow from investing activities (B	Operating profit before working capital changes					341.3
rrander deviables Loans and Advances Loans and Advances Loner Non Current assets Inventories Other Von Current assets Other Current mancial Assets Adjustments for Increase / Idecrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Differ Current financial liabilities Differ Current financial liabilities Borrowings Other current financial liabilities Other current financial liabilities Differ Current financial liabilities Differ Current financial liabilities Borrowings Differ current financial liabilities Differ current financial liabi	Changes in working capital: (Refer Note 40)			169.84		404.2
rrander deviables Loans and Advances Loans and Advances Loner Non Current assets Inventories Other Von Current assets Other Current mancial Assets Adjustments for Increase / Idecrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Differ Current financial liabilities Differ Current financial liabilities Borrowings Other current financial liabilities Other current financial liabilities Differ Current financial liabilities Differ Current financial liabilities Borrowings Differ current financial liabilities Differ current financial liabi	Adjustments for (increase) / decrease in operating assets:		a characteris			1.00
Leans and Advances Other Non Current assets Internetions Other Non Current assets Internetions I	Financial Assets	diana inter		and and	Station 1	135
Other Non-Current assets						
Inventories -143.46 -285.84 Other Current Basets -28.35 -570.00 Other Current Basets -13.76 9.35 Adjustments for Increase / (decrease) in operating liabilities: -143.46 -28.35 Trade payables -13.76 9.35 Borrowings -12.40 -10.00 Other current financial liabilities -92.46 9.71 Other current financial liabilities -92.46 9.71 Other current liabilities -92.46 9.71 Other current liabilities, net -12.40 -100.09 Provisions 5.46 -25.01 Deferred tax on amalgamation -6.50 -20.11 Cash flow from operating activities (A) -345.47 100.24 Ast HCOW ROM INVESTING ACTIVITIES -20.11 -101.79 Orceads from analy of fixed deposits -20.11 -101.79 roceads from such of fixed deposits -36.57 -126.58 roceads from such of fixed deposits -31.67 -186.76 robustings -91.87 -186.76 opsyment of Short term Borrowings -31.87 -186.76 organice costs -1.38 -122.29 6.71 ther equity Adjustment ash frequivalents (A) -1.22.39 6.71 <td></td> <td>A State</td> <td>-1,315.02</td> <td></td> <td>-401.66</td> <td></td>		A State	-1,315.02		-401.66	
Other Current assets -143.46 -285.84 Other Current financial Asets -283.5 570.00 Other Current financial Asets -1.03.0 -1.03.0 Adjustments for increase / (decrease) in operating liabilities: -1.290.37 -1.83.47 Trade payables -2.29.35 -2.20.17 Borrowings -1.20.037 -1.83.47 Other current financial liabilities -2.246 9.71 Current tailabilities, net -1.22.40 -1.00.9 Other current financial liabilities -2.45.77 -1.00.24 Deferred tax on amalgamation 5.46 -15.79 Cash generated from operating activities (A) -5.46 -2.20.1 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 Apital expenditure on fixed assets, including capital advances -2.0.11 -101.79 Refer Note (III) below) -1.51.23 79.23 Provisions -2.0.11 -101.79 -100.86 Cothers -0.96 93 -146.76 Cothers -1.66.76 92.15 -100.86 Cothers -1.22.9 -6.71 -100.86 Cothers -1.87 -12.2.9 -6.71 Cothers -1.88.7 -1.86.76 92.2.6 <					-0.73	
Other basks -28.35 570.00 Other basks -1.00 9.35 Adjustments for increase / (decrease) in operating liabilities: -1.00 9.35 Trade payables 3.290.37 -1.83.47 Borrowings -2.246 9.71 Other current financial liabilities -2.46 9.71 Deferred tax on amalgamation -1.45.77 100.24 Cash generated from operating activities (A) -3.46 -2.20 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 Trade specification -3.45 -3.45 Others -3.85 -3.85 Other current financial activities (B) -3.95 -3.00 ASH FLOW FROM INVESTING ACTIVITIES -3.45 -3.00 Others -3.85 -3.87 -3.85 Others -3.85 -3.85 -3.85 Others <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Other Current financial Assets -10,76 -10,76 Adjustments for increase / (decrease) in operating liabilities: -19,76 9,35 Trade payables 1,290,37 -183,47 Other Current financial liabilities -92,46 9,71 Current tax liabilities, net -12,40 -100,90 Cash generated from operating activities (A) -5,46 -22,201 Cash Generations -151,23 79,233 Aptile expenditure on fixed assets, including capital advances -20,11 -101,79 Aptile expenditure on fixed assets, including capital advances -20,211 -101,79 Aptile expenditure on fixed assets, including capital advances -20,211 -101,79 Cotters -0.96 -9,93 -100,86 Others -0.96 -9,93 San (LOW FROM FINANCINE ACTIVITIES<		3 3 3			-285.84	31
Adjustments for increase / (decrease) in operating liabilities: -13.76 9.35 Trade payables 1,290.37 -183.47 Borrowings 0,246 9.71 Other current financial liabilities -22.46 9.71 Current tax liabilities, net -12.40 -10.09 Provisions 5.46 -15.79 Cesh generated from operations 6.50 Vet income tax paid -145.77 100.24 Cash generated from operating activities (A) -5.46 -22.01 Abstract (iii) below) -151.23 79.23 Corected from investing activities (B) -20.11 -101.79 Abstract (iii) below) -20.11 -101.79 Corected from investing activities (B) 0.96 0.93 Abstract (iii) below) -166.76 -19.15 Corected from investing activities (B) -100.86 -100.86 Corected from issue of equity shares -13.87 -106.76 Payment of Borrowings -91.87 -12.29 68.45 Corected in financing activities (C) -158.08 172.26 Corected in financing activities (C) -158.08 172.26 Corected in financing activities (C) -13.54 -7.84 Corected in financing activities (C) -13.84 <td></td> <td></td> <td>-28.35</td> <td>ALL MADE</td> <td>570.00</td> <td></td>			-28.35	ALL MADE	570.00	
Adjustments for increase / (decrease) in operating liabilities: 3.33 Trade payables 3.290.37 Borrowings 3.290.37 Other current financial liabilities -92.46 Current tax liabilities, net -92.46 Deferred tax on amalgamation -12.40 Cash generated from operating activities (A) -145.77 Cash generated from operations -145.77 Vet income tax paid -151.23 Cash generated from operating activities (A) -151.23 ASH FLOW FROM INVESTING ACTIVITIES -101.79 Applied layenditure on fixed assets, including capital advances -20.11 Refer Note (II) below) -101.79 vestment -3.66 Subsidiaries -91.87 Cash (used In) / flow from investing activities (B) 0.96 Subsidiaries -12.20 cash (used In) / flow from investing activities (B) -100.66 coreceds from issue of equity shares -186.76 and cash equivalents at the beginning of the year 138.8 core (Grants -186.76 payment of Borrowings -146.54 core (Grants -186.76 payment of borrowings -186.76 core (Grants -188.17 cand cash equivalents at the beginning of the year <t< td=""><td>Other Current financial Assets</td><td>No. 1 Contraction</td><td></td><td>A SAMATA</td><td>-1.00</td><td></td></t<>	Other Current financial Assets	No. 1 Contraction		A SAMATA	-1.00	
Trade payables 1,290.37 -183.47 Other current financial liabilities 92.46 9.71 Other current liabilities 12.40 -10.09 Current tax ibilities, net 12.40 -10.09 Provisions 5.46 -15.79 Deferred tax on amalgamation 6.50 -145.77 Cash generated from operations -145.77 100.28 Vet income tax paid -5.46 -22.01 Cash flow from operating activities (A) -151.23 79.23 Applied expenditure on fixed assets, including capital advances -20.11 -101.79 Applied ispenditure on fixed assets, including capital advances -20.11 -101.79 Vet income at paid -3.45 -3.45 Cohers -3.95 -3.46 Others -3.96 -3.93 Conceeds from investing activities (B) -3.91 -100.86 ASH FLOW FROM FINANCING ACTIVITIES -3.87 -186.76 Cothers -3.83 -122.58 -100.86 Cothers -3.83 -122.58 -100.86 Cothers -3.83 -122.52 -100.86 Cothers -3.83 -122.52 -100.86 Cothers -3.81 -122.52 -100.86		Called Street	-19.76	A State State	9.35	12.00
Trade payables 1,290.37 -183.47 Other current financial liabilities 92.46 9.71 Other current liabilities 12.40 -10.09 Current tax ibilities, net 12.40 -10.09 Provisions 5.46 -15.79 Deferred tax on amalgamation 6.50 -145.77 Cash generated from operations -145.77 100.28 Vet income tax paid -5.46 -22.01 Cash flow from operating activities (A) -151.23 79.23 Applied expenditure on fixed assets, including capital advances -20.11 -101.79 Applied ispenditure on fixed assets, including capital advances -20.11 -101.79 Vet income at paid -3.45 -3.45 Cohers -3.95 -3.46 Others -3.96 -3.93 Conceeds from investing activities (B) -3.91 -100.86 ASH FLOW FROM FINANCING ACTIVITIES -3.87 -186.76 Cothers -3.83 -122.58 -100.86 Cothers -3.83 -122.58 -100.86 Cothers -3.83 -122.52 -100.86 Cothers -3.83 -122.52 -100.86 Cothers -3.81 -122.52 -100.86	Adjustments for increase / (decrease) in operating lighilities:			1.		
Other current financial liabilities -92.46 9.71 Other current liabilities -92.46 9.71 Other current liabilities -12.40 -10.09 Provisions 5.46 -115.79 Deferred tax on amalgamation -5.46 -22.01 Cash generated from operating activities (A) -5.46 -22.01 ASH FLOW FROM INVESTING ACTIVITIES -101.79 79.23 Cash flow from operating activities (B) -101.79 79.23 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 Cash flow from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 Cockeds from investing activities (B) 0.96 0.93 ASH LOW FROM Financing activities (B) -100.86 -100.86 Cockeds from investing activities (C) -138.7 -136.76 Depayment of Short term Borrowings -13.88 -126.58 Dot Grants 1.38 172.26 Ash How (used in) financing activities (C) -125.58 -7.84 Add cash equivalents (A+B+C) -145.77 -126.58 and cash equivalents (A+B+C) -138.08 -7.84 Add cash equivalents (A+B+C) -7.25 -7.84 Add cash equivalents (A+B+C) -7.84	Trade payables	C. Contractor				
Other current liabilities -3-2.46 9.71 Current tax liabilities, net -12.40 -10.09 Provisions 5.46 -15.79 Deferred tax on amalgamation 5.46 -22.01 Cash generated from operating activities (A) -145.77 100.24 ASH FLOW FROM INVESTING ACTIVITIES -151.23 -79.23 ASH FLOW FROM INVESTING ACTIVITIES -101.79 -101.79 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 ASH FLOW FROM INVESTING ACTIVITIES -20.11 -101.79 Others 0.96 0.93 Cash (used in) / flow from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 Coreceds from issue of equity shares -91.87 -186.76 payment of Borrowings -248.57 -126.58 payment of Short term Borrowings 1.38 172.26 Differences on translation of foreign -145.54 -746.74 and cash equivalents (A+B+C) -126.59 -126.58 and cash equivalents (A+B+C) -126.29 6.71 and cash equivalents (A+B+C) -145.54 -746.74 and cash equivalents (A+B+C)			1,290.37	100000	-183.47	Population 1
Current tax liabilities, net -12.40 -0.03 Deferred tax on amalgamation -10.03 -15.79 Cash generated from operations -145.77 101.24 Staf generated from operations -145.77 101.24 Cash generated from operations -15.23 -22.01 ASH FLOW FROM INVESTING ACTIVITIES -101.79 -22.01 Applied expenditure on fixed assets, including capital advances -20.11 -101.79 Refer Note (iii) below) -0.06 0.93 Others -0.05 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 Others -10.07 Cash (used in) / flow from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 Ordered star and ash equivalents (A+B+C) -126.58 anance costs -126.58 -126.58 epayment of Short term Borrowings 1.38 172.26 ord cash equivalents (A+B+C) -126.59 -126.58 and cash equivalents (A+B+C) -145.44 7.84 and cash equivalents (A+B+C) -145.44 -186.76 and cash equivalents (A+B+C) -126.58 -126.58 and cash equivalents (A+B+C) -146.54 -126.58 and cash equivalents (A+B+C)	Other current financial liabilities			C. Law St.		
Provisions 5.46 -15.79 Deferred tax on amalgamation 5.46 -15.79 Cash generated from operating activities (A) -145.77 100.24 ASH FLOW FROM INVESTING ACTIVITIES -5.46 -22.01 Capital expenditure on fixed assets, including capital advances -20.11 -101.79 Refer Note (iii) below) rocceds from maturiy of fixed deposits -20.01 -101.79 vostment 0.96 0.93 - -Others 0.96 0.93 - cash (used in) / flow from investing activities (B) 0.96 0.93 - ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 cash (used in) / flow from investing activities (B) 0.96 0.93 - ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 - rocceds from issue of equity shares -91.87 -186.76 - apayment of Short term Borrowings 948.57 -126.58 - payment of Short term Borrowings 1.38 172.26 - decrease) in Cash and cash equivalents (A+B+C) 1.38 7.24 - and cash equivalents at the beg	Other current liabilities				9.71	S. S. Star
Provisions 5.46 -15.79 Deferred tax on amalgamation 5.46 -15.79 Cash generated from operating activities (A) -145.77 100.24 ASH FLOW FROM INVESTING ACTIVITIES -5.46 -22.01 Capital expenditure on fixed assets, including capital advances -20.11 -101.79 Refer Note (iii) below) rocceds from maturiy of fixed deposits -20.01 -101.79 vostment 0.96 0.93 - -Others 0.96 0.93 - cash (used in) / flow from investing activities (B) 0.96 0.93 - ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 cash (used in) / flow from investing activities (B) 0.96 0.93 - ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 - rocceds from issue of equity shares -91.87 -186.76 - apayment of Short term Borrowings 948.57 -126.58 - payment of Short term Borrowings 1.38 172.26 - decrease) in Cash and cash equivalents (A+B+C) 1.38 7.24 - and cash equivalents at the beg	Current tax liabilities, net		and a subsection.		-10.09	2000
Cash generated from operations	Provisions		5.46		-15.79	
Cash generated from operations	Deferred tax on amalgamation		1000		6.50	
Vet income tax paid -145.77 101.24 t cash flow from operating activities (A) -5.46 -22.01 ASH FLOW FROM INVESTING ACTIVITIES -151.23 79.23 Capital expenditure on fixed assets, including capital advances -20.11 -101.79 Viroceeds from maturity of fixed deposits -20.11 -101.79 viroceeds from maturity of fixed deposits -20.96 0.93 viroceeds from maturity of fixed deposits 0.96 0.93 viroceeds from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 cosed (used in) / flow from investing activities (B) -19.15 -100.86 structure from issue of equity shares - - - nance costs -91.87 -186.76 - epayment of Borrowings -91.87 -126.58 - payment of short term Borrowings 1.38 172.26 - ict of exchange differences on translation of foreign trency Cash and cash equivalents (A+B+C) - - - and cash equivalents at the end of the year (Refer Note (I) below) - - - - iprice:	Cash generated from operations	-			Mark States	2.2
ic cash flow from operating activities (A) -5.46 -22.01 ASH FLOW FROM INVESTING ACTIVITIES 79.23 apital expenditure on fixed assets, including capital advances -20.11 -101.79 (Refer Note (iii) below) -20.11 -101.79 rocceds from maturiy of fixed deposits - - ovestment - - - Others 0.96 0.93 - Others 0.96 0.93 - Cash (used in) / flow from investing activities (B) - - ASH FLOW FROM FINANCING ACTIVITIES -100.86 - rocceeds from issue of equity shares - - nance costs -91.87 -186.76 epayment of Borrowings 248.57 -126.58 port Grants 1.38 172.26 ther equity Adjustment - - cash flow (used in) financing activities (C) - 100.97 and cash equivalents at the beginning of the year - - ect of exchange differences on translation of foreign - - rest of exchange differences on translation of foreign - - rest with Banks <td>Vet Income tax paid</td> <td>11000</td> <td></td> <td>-145.77</td> <td></td> <td>101.24</td>	Vet Income tax paid	11000		-145.77		101.24
ASH FLOW FROM INVESTING ACTIVITIES -151.23 79.23 Capital expenditure on fixed assets, including capital advances -20.11 -101.79 Refer Note (iii) below) rocceeds from maturiy of fixed deposits -20.11 -101.79 rocceeds from maturiy of fixed deposits - - - - Subsidiaries 0.96 0.93 - - Others 0.96 0.93 - cash (used in) / flow from investing activities (B) 0.96 0.93 - ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 rocceeds from Issue of equity shares - 68.45 - nance costs -91.87 -186.76 - - epayment of Borrowings 248.57 -126.58 - - - payment of short term Borrowings 1.38 172.26 -	cash flow from operating activities (A)			-5.46	Second and	and the second se
Tapital expenditure on fixed assets, including capital advances -20.11 -101.79 (Refer Note (iii) below) rocceeds from maturity of fixed deposits - rocceeds from maturity of fixed deposits - - vestment - - - Subsidiaries 0.96 0.93 - Others 0.96 0.93 cash (used in) / flow from investing activities (B) - - ASH FLOW FROM FINANCING ACTIVITIES - - rocceeds from Issue of equity shares - 68.45 nance costs - - - epayment of Borrowings 248.57 - - epayment of short term Borrowings 1.38 172.26 - with Grants 1.38 172.26 - ther equity Adjustment - - - cash flow (used in) financing activities (C) - 100.97 - add cash equivalents at the beginning of the year - - - - iet of exchange differences on translation of foreign rency Cash and cash equivalents at the end of the year (Refer Note (i) below) - - - - <t< td=""><td>ASH FLOW FROM INVESTING ACTIVITIES</td><td></td><td></td><td>-151.23</td><td></td><td></td></t<>	ASH FLOW FROM INVESTING ACTIVITIES			-151.23		
Interer Note (III) below) 101.79 Increased from maturity of fixed deposits 101.79 Increased from issue of equity shares 101.79 Increased from issue of equity Adjustment 1.38 Increase for exchange differences on translation of foreign 12.29 Increase equivalents at the beginning of the year 12.29 Increase equivale	apital expenditure on fixed assets, including capital advances				1.8. 1. 1. 1. 1	
Increases from maturity of fixed deposits westment - Subsidiaries - Others cash (used in) / flow from investing activities (B) ASH FLOW FROM FINANCING ACTIVITIES rocceds from issue of equity shares nance costs epayment of short term Borrowings Payment Paym	Neter Note (III) below)		-20.11	13 C 7 C	-101.79	
nvestment - Subsidiaries - 0.96 - 0.93 - Others 0.96 0.93 cash (used in) / flow from investing activities (B) - 19.15 - 100.86 ASH FLOW FROM FINANCING ACTIVITIES - 19.15 - 100.86 rocceds from issue of equity shares 68.45 - nance costs -91.87 - 186.76 epayment of Borrowings 248.57 - 126.58 poy of Grants 1.38 172.26 ovt Grants 1.38 172.26 ther equity Adjustment - 100.97 cash flow (used in) financing activities (C) 158.08 28.34 decrease) in Cash and cash equivalents (A+B+C) 14.54 7.84 and cash equivalents at the beginning of the year -12.29 6.71 iect of exchange differences on translation of foreign 14.54 7.84 rrency Cash and cash equivalents - - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 oes with Banks - - 0.83 ners - - 0.83	roceeds from maturiy of fixed deposits					
Others 0.96 0.93 cash (used in) / flow from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 rocceeds from issue of equity shares 68.45 nance costs -91.87 -186.76 epayment of Borrowings 248.57 -126.58 epayment of short term Borrowings 248.57 -126.58 out Grants 1.38 172.26 ther equity Adjustment - 100.97 cash flow (used in) financing activities (C) - 100.97 decrease) in Cash and cash equivalents (A+B+C) - - and cash equivalents at the beginning of the year - - ect of exchange differences on translation of foreign 14.54 7.84 rency Cash and cash equivalents - - - and cash equivalents at the end of the year (Refer Note (I) below) 2.25 14.54 nprises: - - - - ces with Banks - - - 0.83 hers - - - 0.83	Ivestment					
cash (used in) / flow from investing activities (B) 0.96 0.93 ASH FLOW FROM FINANCING ACTIVITIES -100.86 rocceeds from issue of equity shares 68.45 nance costs -91.87 -186.76 epayment of Borrowings 248.57 -126.58 payment of short term Borrowings 1.38 172.26 ovt Grants 1.38 172.26 ther equity Adjustment - 100.97 cash flow (used in) financing activities (C) - 100.97 decrease) in Cash and cash equivalents (A+B+C) - - and cash equivalents at the beginning of the year - - ect of exchange differences on translation of foreign - - rrency Cash and cash equivalents - - and cash equivalents at the end of the year (Refer Note (i) below) - - apprises: - - - ces with Banks - - - hers - - - and cash equivalents at the end of the year (Refer Note (i) below) - - - ners - - - - </td <td>- Subsidiaries</td> <td></td> <td></td> <td>State of the</td> <td></td> <td>2</td>	- Subsidiaries			State of the		2
ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 rocceeds from issue of equity shares - 68.45 nance costs -91.87 -186.76 epayment of Borrowings 248.57 -126.58 port Grants 1.38 172.26 ott Grants - 100.97 ther equity Adjustment - 100.97 cash flow (used in) financing activities (C) - 100.97 decrease) in Cash and cash equivalents (A+B+C) - 100.97 and cash equivalents at the beginning of the year - - ect of exchange differences on translation of foreign 14.54 7.84 rency Cash and cash equivalents - - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 nprises: - - - ces with Banks - - - hers - - 13.71 0.83 - - 0.83				1000	- D	1.1
ASH FLOW FROM FINANCING ACTIVITIES -19.15 -100.86 rocceeds from issue of equity shares - 68.45 nance costs -91.87 -186.76 epayment of Borrowings 248.57 -126.58 port Grants 1.38 172.26 ott Grants - 100.97 ther equity Adjustment - 100.97 cash flow (used in) financing activities (C) - 100.97 decrease) in Cash and cash equivalents (A+B+C) - 100.97 and cash equivalents at the beginning of the year - - ect of exchange differences on translation of foreign 14.54 7.84 rency Cash and cash equivalents - - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 nprises: - - - ces with Banks - - - hers - - 13.71 0.83 - - 0.83	cash (used in) / flow from investing activities (B)		0.96		0.93	
roceeds from issue of equity shares nance costs epayment of Borrowings epayment of Borrowings epayment of short term Borrowings out Grants ther equity Adjustment cash flow (used in) financing activities (C) decrease) in Cash and cash equivalents (A+B+C) and cash equivalents at the beginning of the year ect of exchange differences on translation of foreign rrency Cash and cash equivalents and cash equivalents at the end of the year (Refer Note (i) below) aprises: ces with Banks hers	ASH FLOW FROM FINANCING ACTIVITIES			-19.15		-100.86
nance costs 68.45 payment of Borrowings 68.45 payment of short term Borrowings 248.57 payment of short term Borrowings 248.57 248.57 1.38 1.38 1.38 1.38 1.72.26 100.97 100.97 100.97 28.34 decrease) In Cash and cash equivalents (A+B+C) and cash equivalents at the beginning of the year ect of exchange differences on translation of foreign rrency Cash and cash equivalents and cash equivalents at the end of the year (Refer Note (i) below) aprises: ces with Banks hers 2.25 1.38 1.38 1.38 1.38 1.38 1.38 1.38 1.38 1.38 1.38 1.2.29 6.71 1.54 2.25 14.54 1.371 2.25 0.83	oceeds from issue of equity shares		Sec. Sugar			
and cash equivalents at the end of the year (Refer Note (i) below) 248.57 -126.58 1.38 172.26 100.97 158.08 28.34 248.57 100.97 25 14.54 26.71 7.84 7.225 14.54 100.97 158.08 100.97 158.08 100.97 100.97	nance costs				68.45	
and cash equivalents at the end of the year (Refer Note (i) below) 248.57 -126.58 1.38 172.26 100.97 158.08 28.34 248.57 100.97 25 14.54 26.71 7.84 7.225 14.54 100.97 158.08 100.97 158.08 100.97 100.97	payment of Borrowings		A STATE OF			
1.38 172.26 ther equity Adjustment 100.97 tash flow (used in) financing activities (C) 158.08 28.34 decrease) in Cash and cash equivalents (A+B+C) 12.29 6.71 and cash equivalents at the beginning of the year 14.54 7.84 rect of exchange differences on translation of foreign 14.54 7.84 rrency Cash and cash equivalents 2.25 14.54 and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 nprises: 2.25 14.54 13.71 ces with Banks - - 13.71 ners - - 0.83	payment of short term Borrowings		248.57		Contraction of the second second	315 A
ther equity Adjustment cash flow (used in) financing activities (C) decrease) in Cash and cash equivalents (A+B+C) and cash equivalents at the beginning of the year ect of exchange differences on translation of foreign rency Cash and cash equivalents and cash equivalents at the end of the year (Refer Note (i) below) nprises: ces with Banks hers 28.34 -12.29 6.71 100.97 28.34 -12.29 6.71 14.54 7.84 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.29 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.84 -12.25 14.54 7.8	ovt Grants		1.38			
cash flow (used in) financing activities (C) 100.97 decrease) In Cash and cash equivalents (A+B+C) 158.08 and cash equivalents at the beginning of the year -12.29 ect of exchange differences on translation of foreign 14.54 rrency Cash and cash equivalents 7.84 and cash equivalents at the end of the year (Refer Note (i) below) 2.25 nprises: - ces with Banks - ners - 2.25 0.83						
decrease) In Cash and cash equivalents (A+B+C) 158.08 28.34 and cash equivalents at the beginning of the year -12.29 6.71 iect of exchange differences on translation of foreign 14.54 7.84 rrency Cash and cash equivalents - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 nprises: - - 13.71 ces with Banks - - 13.71 ners - - 0.83	ash flow (used in) financing activities (C)		-		100.97	
decrease) in Cash and cash equivalents (A+B+C) -12.29 6.71 and cash equivalents at the beginning of the year 14.54 7.84 rect of exchange differences on translation of foreign 14.54 7.84 rrency Cash and cash equivalents - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 oprises: - - - ces with Banks - - 13.71 ners - - 0.83			3 6	158.08		28.34
and cash equivalents at the beginning of the year -12.29 6.71 iect of exchange differences on translation of foreign rrency Cash and cash equivalents 14.54 7.84 and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 oprises: 2.25 14.54 ces with Banks - 13.71 pers 2.25 0.83	decrease) in Cash and cash equivalents (A+B+C)					20.04
ect of exchange differences on translation of foreign 14.54 7.84 rrency Cash and cash equivalents - - and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 or swith Banks - - 13.71 pres - 0.83	and cash equivalents at the beginning of the year		See March	-12.29		6 71
rrency Cash and cash equivalents and cash equivalents and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 ces with Banks hers 2.25 0.83	ect of exchange differences on translation of foreign					
and cash equivalents at the end of the year (Refer Note (i) below) 2.25 14.54 ces with Banks hers 2.25 13.71 2.25 0.83	rency Cash and cash equivalents			-	and the second second	/104
2.25 14.54 ces with Banks hers 2.25 0.83	and cash equivalents at the end of the user in the			all shares		AND A
Ces with Banks 14.34 ners 2.25 0.83	prises:		COLORES STATE	2.25		14.04
13.71 2.25 0.83						14.54
2.25 0.83					again the	12.00
2.26 0.65	BALL THE CONTRACTOR OF A DATE OF A D		S. A. Start	Contract of the second s		
				2.25		0.83

Place: Hyderabad Date: 13.11.2024

Managing Director DIN: 01764665

2

miteo

AT SENIQ P

Denstru L.				(Rs in Lakh
Particulars	As September		As	at
A. CASH FLOW FROM OPERATING ACTIVITIES Profit Before Tax	ouprenine	30, 2024	March 3	1, 2024
Adjustments for :		10.01		
Profit on sale of ASSets	Dia instruction	10.01		55.8
Depreciation and an anti-			- 1917 J	10 10 10 10
Depreciation and amortisation expense Finance costs	67.63		153.82	
Interest income	75.78		158.98	
Provision for Gratutiy	-0.96		-0.93	
contraction of actually		and the second	0.55	
Operating profit before working capital changes		142.45	Stations and	311.8
Changes in working capital: (Refer Note 40)		152.46		367.7
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables			A State Prove	
Loans and Advances	-909.26	Contraction of	-471.53	1.186.1
Other Non Current assets			-0.73	ase and a
Inventories	A CONTRACT	Sec. 1		
Other Current assets	21.80	Sign alight	-99.53	States 1
Other bank balances	-32.70		571.14	and and the state of the state
Other Current financial Assets	TANK BARRIER	and a second	-1.00	Stability .
	-1.46	States a	9.35	See Ok .
Adjustments for increase / (decrease) in operating liabilities:	Part In			The second second
Trade payables		the state	Ter States	
Borrowings	697.34	er and in the	-159.86	
Other current financial liabilities	L'articles a	200	Second States	32. 动于一个!
Other current liabilities	-92.46		9.71	
Current tax liabilities, net	-12.40		-1.01	
Provisions	5.29		-14.53	The state of the
Deferred tax on amalgamation			6.50	
Cash generated from operations			SH S SI	100000000
Net income tax paid		-171.39		216.22
et cash flow from operating activities (A)		-5.29		-20.24
CASH FLOW FROM INVESTING ACTIVITIES		-176.68	Energy Contraction	195.99
Capital expenditure on fixed assets, including capital advances		Sector Sector		
(Refer Note (III) below)	-20.11		-101.79	Seller States
Proceeds from maturiy of fixed deposits	Electric de la	A CANADA A	Sectores in the	
Investment	En se la		CHARLES IN	
- Subsidiaries				228 B.
- Others	0.96		20.00	TENE T
t cash (used in) / flow from investing activities (B)	0.96		0.93	S
CASH FLOW FROM FINANCING ACTIVITIES		-19.15		-120.86
Proceeds from issue of equity shares				
Finance costs	-75.78	303 3	68.45	
Repayment of Borrowings		200.001.0	-158.98	
Repayment of short term Borrowings	-1.29		-99.03	10 10 10
Govt Grants	1.25		19.66	
Other equity Adjustment				
cash flow (used in) financing activities (C)		184.37	100.97	
(d		104.37	1000	-68.94
(decrease) in Cash and cash equivalents (A+B+C)	1222 1222	-11.46		
h and cash equivalents at the beginning of the year	1.188	13.71	Star Van Star	6.19
ffect of exchange differences on translation of foreign		10.71	A SALES	7.52
urrency Cash and cash equivalents				
h and cash equivalents at the end of the year (Refer Note (i) below)		7.75		100
inprises.		2.25		13.71
nces with Banks				
thers		2.25		0.00
		2.25		7.52
		2.23		7.52

Date: 13.11.2024

For Concord Drugs Limited P10 View Managing Director DIN: 01764665



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033 E-mail : info@pkas.in / infoong@pkas.in

GSTIN: 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.

- 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
- 3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

- 1. We nave reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 30 September 2024, and the year to date results for the period 1 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2024 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
- 2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

- 4. The Statement includes the results of the following entities: Proton Remedies Private Limited
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. The accompanying Statement includes the unaudited financial results and other financial information, in respect of one subsidiary, whose unaudited financial results include total revenues of Rs 666.35 lakhs, total net profit after tax of Rs.0.48 lakhs, for the half year ended Sep 30, 2024, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Pundarikashyam and Associates Chartered Accountants FRN: 011330S.

B.Surva Prakasa Rao (Partner) MNo: 205125 UDIN: 24205125BKAFDH2290

> Place: Hyderabad Date: 13-11-2024.



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033 E-mail : info@pkas.in / infoong@pkas.in

GSTIN: 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.

- 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
- 3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

- We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2024, and the year to date results for the period 1 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEB! (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2024 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
- 2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India.

CHYAM

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates Chartered Accountants FRN: 011330S.

B. Surya Prakasa Rao (Partner) MNo: 205125 UDIN: 24205125BKAEDG6249

> Place: Hyderabad Date: 13-11-2024.